Incidence and Severity of Chemotherapy-induced Mucositis: A Cross-sectional Study
Introduction: Chemotherapy-induced Mucositis (CIM) is a debilitating complication in cancer treatment, affecting patient quality of life and often leading to treatment modifications. This study provides a comprehensive analysis of CIM’s incidence, severity, and associated risk factors in chemotherap...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2025-07-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/article_fulltext.asp?issn=0973-709x&year=2025&month=July&volume=19&issue=7&page=XC06-XC12&id=21249 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction: Chemotherapy-induced Mucositis (CIM) is a debilitating complication in cancer treatment, affecting patient quality of life and often leading to treatment modifications. This study provides a comprehensive analysis of CIM’s incidence, severity, and associated risk factors in chemotherapy patients.
Aim: To assess the incidence and severity of CIM and to determine the association between various risk factors of mucositis with the severity of CIM.
Materials and Methods: A cross-sectional study was conducted with 164 adult cancer patients receiving chemotherapy in the Department of Oncology at a tertiary care hospital in Chennai, Tamil Nadu, India from May 2024 to October 2024. Data were gathered on demographics, cancer types, chemotherapy regimens, mucositis grades, and therapeutic interventions. CIM severity was graded as per the Common Terminology Criteria for Adverse Events (CTCAE). Chi-square test was used to analyse the association between the risk factors and the severity of CIM, using Statistical Packages of Social Sciences (SPSS) version 23.0.
Results: The CIM developed in 99 patients (60.36%), with 70 (70.70%) experiencing Grade 2 and 3 severity. Mucositis was predominantly observed in the oral 29 (29.29%) and intestinal 25 (25.25%) regions. Middle-aged patients 41-60 years, those with co-morbid conditions, and patients on docetaxel-based regimens were at increased risk. L-glutamine supplementation was used as a preventive and treatment measure for CIM.
Conclusion: The CIM is a frequent and severe side effect of chemotherapy, particularly among middle-aged patients and those with specific cancer regimens. Findings emphasise the need for preventive and management strategies to mitigate CIM’s impact, enhance patient outcomes, and reduce the burdens of cancer patients. |
|---|---|
| ISSN: | 2249-782X 0973-709X |